- Home
- BAM vs BMY Comparison
BAM vs BMY Comparison
Compare BAM & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAM
- BMY
- Stock Information
- Founded
- BAM 2022
- BMY 1887
- Country
- BAM United States
- BMY United States
- Employees
- BAM N/A
- BMY N/A
- Industry
- BAM
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- BAM
- BMY Health Care
- Exchange
- BAM Nasdaq
- BMY Nasdaq
- Market Cap
- BAM 87.2B
- BMY 95.0B
- IPO Year
- BAM N/A
- BMY N/A
- Fundamental
- Price
- BAM $50.13
- BMY $46.04
- Analyst Decision
- BAM Buy
- BMY Hold
- Analyst Count
- BAM 11
- BMY 11
- Target Price
- BAM $63.34
- BMY $55.64
- AVG Volume (30 Days)
- BAM 2.9M
- BMY 16.0M
- Earning Date
- BAM 11-07-2025
- BMY 10-30-2025
- Dividend Yield
- BAM 3.49%
- BMY 5.40%
- EPS Growth
- BAM 42.52
- BMY N/A
- EPS
- BAM 1.62
- BMY 2.97
- Revenue
- BAM $4,486,000,000.00
- BMY $48,034,000,000.00
- Revenue This Year
- BAM $34.10
- BMY N/A
- Revenue Next Year
- BAM $13.62
- BMY N/A
- P/E Ratio
- BAM $30.96
- BMY $15.47
- Revenue Growth
- BAM 10.85
- BMY 1.26
- 52 Week Low
- BAM $41.78
- BMY $42.52
- 52 Week High
- BAM $64.10
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- BAM 33.41
- BMY 50.61
- Support Level
- BAM $48.68
- BMY $45.27
- Resistance Level
- BAM $52.09
- BMY $49.99
- Average True Range (ATR)
- BAM 1.56
- BMY 1.14
- MACD
- BAM -0.24
- BMY -0.14
- Stochastic Oscillator
- BAM 20.61
- BMY 19.37
About BAM Brookfield Asset Management Inc Limited Voting Shares
Brookfield Asset Management Ltd engages in providing alternative asset management services through an ownership interest in a alternative asset management business. It offers a range of alternative investment products to investors around the world including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies, and private wealth investors.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.